(1) Has a terminal illness;
(2) Has, in consultation with the physician, considered all other treatment options currently approved by the federal Food and Drug Administration;
(3) Has been given a recommendation by the physician for an investigational drug, biological product, or device; and
(4) Has given written informed consent for the use of the investigational drug, biological product, or device.